Stay updated with breaking news from Nasdaq Rnac. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings at ($1.09) […]
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings at […]
Cartesian Therapeutics (NASDAQ:RNAC – Free Report) had its price target upped by HC Wainwright from $2.00 to $54.00 in a research report released on Tuesday, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at […]
Leerink Partnrs reissued their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings […]